<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098514</url>
  </required_header>
  <id_info>
    <org_study_id>03-183</org_study_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>CDR0000400150</secondary_id>
    <secondary_id>NCI-6400</secondary_id>
    <secondary_id>DFCI-IRB-03183</secondary_id>
    <secondary_id>HANABIO-DFCI-02000</secondary_id>
    <nct_id>NCT00098514</nct_id>
  </id_info>
  <brief_title>Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors</brief_title>
  <official_title>A Phase I Study Of PT523 In Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying side effects, best way to give, and best dose of&#xD;
      talotrexin in treating patients with advanced or recurrent solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of talotrexin in patients in patients with advanced&#xD;
           or recurrent solid tumors.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the dose-limiting toxic effects of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Correlate pharmacokinetic parameters of this drug or patient characteristics with&#xD;
           drug-related toxicity in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor efficacy of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive talotrexin IV over 5 minutes on day 1 OR days 1 and 8 OR days 1, 8, and 15.&#xD;
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of talotrexin until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. An additional 6-10 patients are treated at&#xD;
      the MTD.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 9-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2003</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>There were 7 potential PT523 single agent dose levels to be evaluated in this phase I study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Dose Level 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>talotrexin ammonium</intervention_name>
    <arm_group_label>Dose Level 1a</arm_group_label>
    <arm_group_label>Dose Level 1b</arm_group_label>
    <arm_group_label>Dose Level 1c</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of malignant solid tumor&#xD;
&#xD;
               -  Metastatic or inoperable disease&#xD;
&#xD;
          -  No known curative or survival-prolonging palliative therapy exists OR failed these&#xD;
             prior therapies&#xD;
&#xD;
          -  No leukemia&#xD;
&#xD;
          -  No primary CNS tumor&#xD;
&#xD;
          -  No third-space fluid collection (i.e., pleural effusion, ascites)&#xD;
&#xD;
               -  Clinically insignificant small pleural or peritoneal effusions identified by CT&#xD;
                  scan, MRI, or other diagnostic test allowed&#xD;
&#xD;
          -  No active* brain metastases, including the following:&#xD;
&#xD;
               -  Evidence of cerebral edema by CT scan or MRI&#xD;
&#xD;
               -  Progression since prior imaging study&#xD;
&#xD;
               -  Requirement for steroids&#xD;
&#xD;
               -  Clinical symptoms of/from brain metastases NOTE: *Treated and/or stable brain&#xD;
                  metastasis allowed provided patient is asymptomatic&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  RBC folate ≥ lower limit of normal&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other uncontrolled serious medical or psychiatric illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior bone marrow transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 3 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 3 weeks since prior antifolate therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Paul Eder, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 7, 2004</study_first_submitted>
  <study_first_submitted_qc>December 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2004</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Geoffrey Shapiro, MD, PhD</investigator_full_name>
    <investigator_title>Director, Early Drug Development Center</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

